Warren P Mason

Warren P Mason

UNVERIFIED PROFILE

Are you Warren P Mason?   Register this Author

Register author
Warren P Mason

Warren P Mason

Publications by authors named "Warren P Mason"

Are you Warren P Mason?   Register this Author

70Publications

1386Reads

11Profile Views

Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial.

J Neurooncol 2019 May 7;142(3):565-575. Epub 2019 Mar 7.

Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03130-1DOI Listing
May 2019

mTOR inhibition in glioblastoma: requiem for a dream?

Neuro Oncol 2018 04;20(5):584-585

Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892149PMC
April 2018

Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.

Can J Neurol Sci 2018 01 20;45(1):56-61. Epub 2017 Nov 20.

1Department of Medicine,Division of Neurology,University of Toronto,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2017.248DOI Listing
January 2018

Contemporary management of high-grade gliomas.

CNS Oncol 2018 01 15;7(1):51-65. Epub 2017 Dec 15.

Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2017-0026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001673PMC
January 2018

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Neuro Oncol 2017 Aug;19(8):1119-1126

Tel-Aviv Sourasky Medical Center, Tel-Aviv University; European Organization for Research and Treatment of Cancer, Brussels (EORTC); National Institutes of Health (M.R.M.); University of Alabama at Birmingham; Princess Margaret Cancer Centre, University of Toronto; Lausanne University Hospital; NRG Oncology Statistics and Data Management Center; Odette Cancer Centre and Sunnybrook Health Sciences Centre, University of Toronto; Samsung Medical Center, Sungkyunkwan University School of Medicine; Edinburgh Cancer Centre; Mayo Clinic; Robert-Janker Clinic at the University of Bonn Medical Centre, and MAASTRO clinic, GROW School for Oncology, Maastricht University Medical Centre; Miami Cancer Institute; Erasmus University Hospital; Dana-Farber Cancer Institute and Harvard Medical School; University of Zurich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570239PMC
August 2017

Radiation plus Temozolomide in Patients with Glioblastoma.

N Engl J Med 2017 06;376(22):2197

University of Toronto, Toronto, ON, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1704726DOI Listing
June 2017

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

N Engl J Med 2017 03;376(11):1027-1037

From Odette Cancer Centre, Sunnybrook Health Sciences Centre (J.R.P., A.S.) and Princess Margaret Cancer Centre (N.L., W.P.M.), Toronto, the Canadian Cancer Trials Group, Queens University, Kingston, ON (C.J.O., C.W., K.D.), University of Calgary, Calgary, AB (J.G.C.), University of Alberta, Edmonton (W.R.), Quality of Life Consulting, West Vancouver, BC (D.O.), Queen's University, Kingston General Hospital, Kingston, ON (J.P.R.), and Juravinski Cancer Centre, Hamilton, ON (H.H.) - all in Canada; Azienda Unità Sanitaria Locale- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche, Bologna (A.A.B., E.F.), and Fondazione Istituto Neurologico Carlo Besta, Milan (L. Fariselli) - both in Italy; University Hospital Gasthuisberg, Leuven, Belgium (J.M.); Peter MacCallum Cancer Centre, Melbourne, VIC (C.P.), University of Newcastle, Newcastle, NSW (M.F.), University of Queensland, Brisbane (M.F.), and Royal North Shore Hospital, Sydney (M.B.) - all in Australia; Saitama Medical University International Medical Center, Saitama, Japan (R.N.); Hôpital de la Pitié-Salpêtrière (F.L.-D., L. Feuvret), Paris, and Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseilles (O.C.) - both in France; the European Organization for Research and Treatment of Cancer, Brussels (V.G.); the Neurology Clinic, University of Heidelberg, Heidelberg, Germany (A.W., W.W.); Tauranga Hospital, Tauranga, New Zealand (M.T.); and Maastricht University Medical Center and School for Oncology and Developmental Biology, Maastricht, the Netherlands (B.G.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611977DOI Listing
March 2017

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Neuro Oncol 2017 01 31;19(1):89-98. Epub 2016 Aug 31.

UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193027PMC
January 2017

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol 2016 Nov 27;17(11):1533-1542. Epub 2016 Sep 27.

Department of Medical Oncology and Cancer Centre, University Hospital Zurich, Zurich, Switzerland; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC) and GROW (School for Oncology), Maastricht, Netherlands; Department of Radiation-Oncology, MediClin Robert-Janker-Clinic, Clinical Cooperation Unit Neuro-oncology, University Bonn Medical Centre, Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30305-9DOI Listing
November 2016

A critical balance: managing coagulation in patients with glioma.

Expert Rev Neurother 2016 07 9;16(7):803-14. Epub 2016 May 9.

a Pencer Brain Tumor Centre , Princess Margaret Hospital Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2016.1181542DOI Listing
July 2016

Illness intrusiveness and subjective well-being in patients with glioblastoma.

J Neurooncol 2016 Jan 29;126(1):127-135. Epub 2015 Sep 29.

Psychosocial Oncology & Palliative Care, Princess Margaret Cancer Centre, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1943-6DOI Listing
January 2016

Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.

Cancer Immunol Res 2015 Dec 29;3(12):1299-302. Epub 2015 Sep 29.

Princess Margaret Cancer Centre, University Health Network Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0141DOI Listing
December 2015

Phase II study of PX-866 in recurrent glioblastoma.

Neuro Oncol 2015 Sep 20;17(9):1270-4. Epub 2015 Jan 20.

CancerCare Manitoba, Winnipeg, Canada (M.W.P., S.B.); Queen's University, Department of Oncology, Kingston, Canada (E.A.E.); Dalhousie University,Halifax, Canada (M.V.M.); BritishColumbia Cancer Agency, Vancouver, Canada (B.T.); Tom Baker Cancer Centre, Calgary, Canada (J.C.E.); London Regional Cancer Program, London, Canada (D.R.M.); University of Alberta, Edmonton, Canada (D.D.E.); Allan Blair Cancer Center, Regina, Canada (A.S.K., M.S., H.C.); Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada (J.S.); Department of Pathology, University Health Network, University of Toronto, Toronto, Canada (M.S.T., S.K.-R.); NCIC Clinical Trials Group, Queen's University, Kingston, Canada (D.T., J.P.); Oncothyreon, Inc., Seattle, Washington (D.F.H.); Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada (W.P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou365DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588751PMC
September 2015

Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.

Authors:
Warren P Mason

Neuro Oncol 2015 Sep 1;17(9):1181-2. Epub 2015 Jul 1.

Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada (W.P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588763PMC
September 2015

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

J Clin Oncol 2015 Jul 26;33(19):2166-75. Epub 2015 May 26.

Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Umeå University, Umeå, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University Hospital of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Frank Saran, The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom; Ryo Nishikawa, Saitama Medical University, Saitama, Japan; Magalie Hilton, F. Hoffmann-La Roche, Basel, Switzerland; Olivier L. Chinot, Service de Neuro-Oncologie, Aix-Marseille University, Assistance Publique- Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3217DOI Listing
July 2015

End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.

Authors:
Warren P Mason

Neuro Oncol 2015 May 13;17(5):634-5. Epub 2015 Feb 13.

Department of Medicine, Princess Margaret Cancer Centre and University of Toronto.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482863PMC
May 2015

Bevacizumab in recurrent glioblastoma: five informative patient scenarios.

Authors:
Warren P Mason

Can J Neurol Sci 2015 May 8;42(3):149-56. Epub 2015 Apr 8.

Department of Medicine,Princess Margaret Cancer Centre and University of Toronto,Toronto,Ontario,Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2015.21DOI Listing
May 2015

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

Neuro Oncol 2015 Mar 19;17(3):430-9. Epub 2014 Aug 19.

Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.); University of Alabama, Birmingham, Alabama (L.B.N.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Odette Cancer Centre, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Barrow Neurological Institute, Phoenix, Arizona (W.S.); Department of Medical Oncology, McGill University, Montréal, Quebec, Canada (P.K.); Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada (D.M.); Johnnie Cochran Brain Tumor Center, Cedars-Sinai Medical Center, Los Angeles, California (S.P., A.C.); Boehringer Ingelheim R.C.V GmbH & Co KG, 1120 Vienna, Austria (A.C.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut (Y.F., J.C.); Boehringer Ingelheim Pharma GmbH & Co. K.G., 88400 Biberach, Germany (S.S.W.); CancerCare Manitoba, Winnipeg, Manitoba, Canada (D.D.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483093PMC
March 2015

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Neuro Oncol 2014 Nov 4;16(11):1541-6. Epub 2014 Jul 4.

Departments of Neurology (A.B.L., F.M.I., L.E.A., L.M.D.), Pathology (S.C.J., M.K.R.), Epidemiology & Biostatistics (A.S.R., K.S.P.), and the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York; University of California, Los Angeles, Los Angeles, California (T.F.C.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (K.D.A., A.L.R.); Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (A.F.E., D.N.L.); NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, University of Chicago, Pritzker School of Medicine, Evanston, Illinois (N.A.P.); London Regional Cancer Program, London, Ontario, Canada (B.J.F.); Barrow Neurological Institute, Phoenix, Arizona (L.S.A.); University of Calgary, Calgary, Alberta, Canada (J.G.C., G.B.R.U.); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts (P.Y.W.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Children's Hospital Boston, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Wisconsin, Madison, Wisconsin (H.I.R., B.G.R.); University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington (M.C.C.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Albany Medical Center, Albany, New York (S.A.W.); Kaiser Permanente-Los Angeles Medical Center, Los Angeles, California (R.M.G.); Clemenceau Medical Center, Beirut, Lebanon and Université Saint-Esprit de Kaslik, Byblos, Lebanon (F.G.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201067PMC
November 2014

Are patients open to elective re-sampling of their glioblastoma? A new way of assessing treatment innovations.

Acta Neurochir (Wien) 2014 Oct 2;156(10):1855-62; discussion 1862-3. Epub 2014 Aug 2.

Division of Neurosurgery, Toronto Western Hospital, University of Toronto, West Wing, 4th Floor Rm 4 W448, 399 Bathurst St., Toronto, ON, M5T2S8, Canada,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00701-014-2189-3
Publisher Site
http://dx.doi.org/10.1007/s00701-014-2189-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167439PMC
October 2014

Seizure management in patients with gliomas.

Expert Rev Neurother 2014 Apr 19;14(4):367-77. Epub 2014 Feb 19.

University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737175.2014.890890DOI Listing
April 2014

Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.

Lancet Neurol 2014 Mar 22;13(3):276-86. Epub 2014 Jan 22.

August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; Hospital Clinic, University of Barcelona, Barcelona, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(13)70299-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838043PMC
March 2014

Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

J Neurooncol 2014 Mar 29;117(1):153-60. Epub 2014 Jan 29.

Department of Medical Oncology, Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1368-7DOI Listing
March 2014

Glioblastoma management in the temozolomide era: have we improved outcome?

J Neurooncol 2013 Nov 25;115(2):303-10. Epub 2013 Aug 25.

Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-013-1230-3DOI Listing
November 2013

Emerging biomarkers in glioblastoma.

Cancers (Basel) 2013 Aug 22;5(3):1103-19. Epub 2013 Aug 22.

Pencer Brain Tumor Centre, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers5031103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795381PMC
August 2013

Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.

CNS Oncol 2013 Jul;2(4):351-8

Pencer Brain Tumor Centre, Princess Margaret Cancer Center, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns.13.26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166534PMC
July 2013

Anaplastic oligodendroglioma: advances and treatment options.

Curr Treat Options Neurol 2013 Jun;15(3):289-301

Pencer Brain Tumor Centre, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11940-013-0218-9
Publisher Site
http://dx.doi.org/10.1007/s11940-013-0218-9DOI Listing
June 2013

Management of glioblastoma in the elderly.

Clin Adv Hematol Oncol 2012 Jun;10(6):379-86

Princess Margaret Hospital, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
June 2012

Antiangiogenic therapies in glioblastoma multiforme.

Expert Rev Anticancer Ther 2012 May;12(5):643-54

Pencer Brain Tumor Centre, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.35DOI Listing
May 2012

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

J Neurooncol 2012 Apr 3;107(2):343-9. Epub 2011 Nov 3.

Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-011-0747-6DOI Listing
April 2012

Anaplastic astrocytomas.

Handb Clin Neurol 2012 ;105:451-66

Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-53502-3.00002-1DOI Listing
April 2012

Right frontal lobe mediation of recollection- and familiarity-based verbal recognition memory: evidence from patients with tumor resections.

J Cogn Neurosci 2011 Dec 12;23(12):3804-16. Epub 2011 May 12.

Rotman Research Institute, Baycrest, 3560 Bathurst Street, Toronto, ON M6A 2E1 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1162/jocn_a_00050DOI Listing
December 2011

Leptomeningeal gliomatosis as the initial presentation of gliomatosis cerebri.

J Neurooncol 2010 Oct 10;100(1):145-9. Epub 2010 Feb 10.

Faculty of Medicine, UME Office, Health Sciences Centre, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, T2N 4N1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-010-0138-4DOI Listing
October 2010

Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Core Evid 2010 Jun 15;4:93-111. Epub 2010 Jun 15.

Department of Medicine, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899776PMC
June 2010

Low-grade oligodendroglioma: current treatments and future hopes.

Expert Rev Anticancer Ther 2009 Nov;9(11):1651-61

Room 7-702, Princess Margaret Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.127DOI Listing
November 2009

Management of malignant melanoma: best practices.

J Cutan Med Surg 2009 Mar-Apr;13(2):55-73

Cross Cancer Institute, Edmonton, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2310/7750.2008.08029DOI Listing
July 2009

A novel tool to analyze MRI recurrence patterns in glioblastoma.

Neuro Oncol 2008 Dec 31;10(6):1019-24. Epub 2008 Jul 31.

Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/15228517-2008-058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718999PMC
December 2008

Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas.

Neurology 2008 Jul;71(5):365-73

Department of Medicine, the University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000319721.98502.1bDOI Listing
July 2008

Emerging drugs for malignant glioma.

Authors:
Warren P Mason

Expert Opin Emerg Drugs 2008 Mar;13(1):81-94

Princess Margaret Hospital, Department of Medicine, 610 University Avenue, Suite 18-717, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.13.1.81 DOI Listing
March 2008

Verbal fluency, trail making, and Wisconsin Card Sorting Test performance following right frontal lobe tumor resection.

J Clin Exp Neuropsychol 2008 Jan 11;30(1):18-32. Epub 2007 Apr 11.

Rotman Research Institute, Baycrest, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13803390601161166DOI Listing
January 2008

The changing management of low-grade astrocytomas and oligodendrogliomas.

Hematol Oncol Clin North Am 2006 Dec;20(6):1249-66

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Room 5-110, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2006.09.003DOI Listing
December 2006

Recent advances in the treatment of oligodendrogliomas.

Curr Neurol Neurosci Rep 2006 May;6(3):212-7

Princess Margaret Hospital, Department of Medicine, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
May 2006

Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Oncologist 2006 Feb;11(2):165-80

Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.11-2-165DOI Listing
February 2006

Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.

Nat Clin Pract Neurol 2005 Dec;1(2):88-95

Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpneuro0045DOI Listing
December 2005

Oligodendroglioma.

Authors:
Warren P Mason

Curr Treat Options Neurol 2005 Jul;7(4):305-314

Department of Medicine, Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
July 2005

Progress in clinical neurosciences: Advances in the management of low-grade gliomas.

Authors:
Warren P Mason

Can J Neurol Sci 2005 Feb;32(1):18-26

Department of Medical Oncology & Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
February 2005

Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings.

Clin Adv Hematol Oncol 2003 Aug;1(8):490

Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
August 2003

Anticonvulsant prophylaxis for patients with brain tumours: insights from clinical trials.

Authors:
Warren P Mason

Can J Neurol Sci 2003 May;30(2):89-90

View Article

Download full-text PDF

Source
May 2003

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.

J Neurosurg 2002 Aug;97(2):341-6

Department of Medicine, Princess Margaret Hospital, and University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://thejns.org/doi/10.3171/jns.2002.97.2.0341
Publisher Site
http://dx.doi.org/10.3171/jns.2002.97.2.0341DOI Listing
August 2002